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PMSF, phenylmethylsulphonyl fluoride; rh123, rhodamine 123; EM, electron 
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Abstract
P-glycoprotein (P-gp) expression at the blood-brain barrier prevents unwanted 
blood-borne toxins and signalling molecules from entering the brain. Primary and 
immortalised human brain endothelial cells (BECs) represent two suitable options for 
studying P-gp function in vitro. The limited supply of primary human BECs and their 
instability over passage number makes this choice unattractive for medium/high 
throughput studies. The aim of this study was to further characterise the expression of 
P-gp by an immortalised human BEC line, hCMEC/D3, in order to evaluate their use 
as an in vitro human blood-brain barrier model. P-gp expression was stable over a 
high passage number (up to passage 38) and was polarised on the apical plasma 
membrane, consistent with human BECs in vivo. In addition, hCMEC/D3 cell P-gp 
expression was comparable, albeit slightly lower to that observed in primary isolated 
human BECs although P-gp function was similar in both cell lines. The P-gp 
inhibitors tariquidar and vinblastine prevented the efflux of rhodamine 123 (rh123) 
from hCMEC/D3 cells, indicative of functional P-gp expression. hCMEC/D3 cells 
also displayed polarised P-gp transport, since both tariquidar and vinblasine 
selectively increased the apical-to-basolateral permeability of hCMEC/D3 cells to 
rh123. The results presented here demonstrate that hCMEC/D3 cells are a suitable 
model to investigate substrate specificity of P-gp in BECs of human origin. 
Key words: P-glycoprotein, brain endothelial cells, blood brain barrier.
- 2 -
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1. Introduction
ATP binding cassette (ABC) transporters at the blood-brain barrier (BBB) 
prevent the entry of unwanted endogenous signalling molecules and toxic xenobiotics 
from the blood into the brain [reviewed in (Loscher and Potschka, 2005)]. To date, at 
least 48 ABC transporter genes have been identified and are classified into seven 
subfamilies, denoted ABCA to ABCG (Dean et al., 2001; Higgins, 1992). 
ABCB1/MDR1 [(P-glycoprotein (P-gp)] is the most extensively studied ABC 
transporter at the BBB, both in vitro and in vivo, and prevents a broad range of 
substances from entering brain tissue, including many therapeutic drugs in use today 
such as anti-epileptics, anti-cancer drugs and HIV protease inhibitors [reviewed in 
(Loscher & Potschka 2005, Schinkel 1999, Zhou 2008)]. 
Structurally, P-gp is arranged into two halves connected by a 75 amino acid 
linker region, with each half consisting of a transmembrane domain (made of 6 
transmembrane segments), an intracellular nucleotide-binding domain and both the N 
and carboxyl termini, which are located intracellularly (Linton, 2007; Schinkel, 1999; 
Schinkel and Jonker, 2003). Conflicting evidence exists as to the expression of P-gp 
by brain endothelial cells (BECs). P-gp expression has been described on the luminal 
membrane of rat brain capillaries (Beaulieu et al. 1997, Miller et al. 2000), isolated 
mouse brain endothelial cells (Tatsuta et al., 1992), and human brain microvessels 
(Seetharaman et al. 1998, Virgintino et al. 2002). In contrast, enhanced abluminal 
expression of P-gp has been observed in rat BECs using transmission electron 
microscopy (EM) techniques (Bendayan et al., 2006). Nevertheless, it is widely 
accepted that P-gp expression is primarily located on the luminal membrane of BECs. 
Whilst multiple studies have been carried out to identify the characteristics of 
P-gp substrates, the most common feature is their hydrophobic nature, which allows 
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them to diffuse across the lipid bilayer relatively easily (Cabrera et al., 2006; 
Cianchetta et al., 2005; Crivori et al., 2006; Penzotti et al., 2002; Wang et al., 2003). 
Indeed, P-gp has been hypothesised to act as a flippase transporter (Schinkel, 1999). 
In vivo data supports the notion of a barrier function for P-gp at the BBB. Mice, 
lacking either mdr1a or combined mdr1a/b genes (equivalent to human ABCB1), 
display enhanced brain accumulation of many P-gp substrates including verapamil, 
indinavir, vinblastine and morphine, when compared to wild type control mice 
[reviewed in (Loscher & Potschka 2005, Miller et al. 2008, Schinkel 1999)]. In 
addition, P-gp inhibition in rats results in increased brain concentrations of colchicine 
and vinblastine (Drion et al., 1996).
In vivo studies represent an important data source for evaluation of ABC 
transporter function at the BBB, but they are highly costly and extrapolation from 
animal models to humans may be problematic due to species differences. For routine 
investigations into P-gp function by human BECs in vitro, there are currently two 
choices, primary and immortalised human BECs. Human primary cell cultures are not 
readily available and, in our experience, do not remain stable over ~ 5 passages, and 
are therefore not suited for routine medium/high throughput studies. hCMEC/D3 cells 
represent the most extensively characterized immortalised human BEC line to date, 
and retain a BEC typical phenotype (Weksler et al. 2005). hCMEC/D3 cells express 
tight junctional proteins and are restrictive to molecules larger than 4 kDa in 
molecular weight, in agreement with in vivo studies (Weksler et al. 2005). Previously, 
P-gp expression by hCMEC/D3 cells has been demonstrated using western blotting 
and mRNA analysis (Weksler et al. 2005). In the same study, an increase in the net 
influx of rhodamine 123 (rh123) was reported following inhibition of P-gp with PSC-
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833, demonstrating that the transporter was indeed functional, as confirmed in a 
recent study (Poller et al., 2008). 
The aim of this study was to further examine P-gp expression and function in 
hCMEC/D3 cells to determine their suitability as an in vitro human BBB model for 
identifying potential P-gp substrates. We first investigated P-gp expression by 
hCMEC/D3 cells, including its subcellular localisation and polarisation, and 
compared it to that of primary human BECs. P-gp functionality in hCMEC/D3 cells 
and primary human BECs was then investigated using rhodamine 123 (rh123) efflux, 
with the 3rd generation P-gp inhibitor tariquidar, or the P-gp competitive substrate 
vinblastine. Finally, using P-gp inhibitors, we investigated the permeability of 
hCMEC/D3 cells to rh123 in order to confirm polarised P-gp function. 
2. Results
2.1 P-gp expression by hCMEC/D3 cells is stable and comparable to that of 
primary human brain endothelial cells
The levels of P-gp expression were compared between hCMEC/D3 cells at 
early passages (between 23 and 28) and primary human BECs (between 2 and 3) to 
determine the suitability of the cell line as an in vitro human BBB model (Fig. 1). 
Both primary human BECs and hCMEC/D3 cells expressed P-gp as demonstrated by 
a higher median fluorescence staining intensity compared to their negative controls 
(Fig. 1a). The levels of P-gp expression by primary human BECs were 30 % higher 
than those expressed by hCMEC/D3 cells, although this difference was not 
statistically significantly different [Fig. 1c, (p = 0.065)]. These results indicate that the 
level of expression of P-gp by hCMEC/D3 cells is close to that of primary human 
BECs. 
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The expression of P-gp by hCMEC/D3 cells over increasing passage (p) 
number was assessed in order to investigate stability of phenotype by this cell line 
(Figs. 1b and c). Using western blotting techniques, P-gp expression was detected as a 
diffuse band of ~ 160 kDa, reflecting different glycosylation patterns of the ABCB1 
product (Ichikawa et al., 1991). P-gp expression was stable between p23 and p38, but 
appeared to decline at higher passages. In contrast, actin levels were maintained with 
the exception of the highest passage investigated (p44), whereas for P-gp expression, 
they declined. When normalised to actin, P-gp was stable up to p38 and decreased by 
~ 35 %, between p38 and p41 (Fig. 1c). 
2.2 Distribution of P-gp expression by hCMEC/D3 cells
We next investigated the sub-cellular localisation of P-gp expression by 
hCMEC/D3 cells. Using fluorescence microscopy, P-gp was not detected in the 
nucleus but appeared to be distributed throughout the cytoplasm and plasma 
membrane (Fig. 2). A cellular fractionation assay was then employed to investigate 
the relative sub-cellular distribution of P-gp. hCMEC/D3 cells were separated into 
cytosolic, membrane/organelle, nuclear and cytoskeletal fractions using differential 
detergent fractionation (Fig. 3a & b). Sp3, a transcription factor, was detected almost 
entirely in the nuclear fraction, whereas actin was expressed highest in the 
cytoskeletal fraction followed by nuclear and membrane fractions. P-gp was 
predominantly, although not exclusively, expressed in the membrane/organelle 
fraction. These results indicate that in hCMEC/D3 cells, P-gp is located on cellular 
membranes, which includes both the plasma membrane and membranes of 
intracellular organelles, in hCMEC/D3 cells. 
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2.3 P-gp expression is polarised to the apical membrane of hCMEC/D3 cells
P-gp expression was then investigated by transmission EM combined with 
immunogold staining (Fig. 4a, b & c), to determine its subcellular localisation. 
Immunolabelling was detected both in the cytoplasm and on the plasma membrane 
(with a distribution pattern of 43 %, and 57 %, respectively). However, the number of 
gold particles associated with the apical plasma membrane was nearly 3 times greater 
than that on the basolateral membrane (Fig. 4d, 66 images analysed over a 500 μm 
section of membrane). Therefore, whilst P-gp molecules appear distributed on both 
membranes and in the cytoplasm, the majority of plasma membrane P-gp was on the 
apical membrane, which is consistent with the blood side in vivo. The localisation of 
P-gp to the apical plasma membrane of hCMEC/D3 cells suggests that this transporter 
may act to prevent the movement of P-gp substrates from the apical to the basolateral 
compartments in in vitro permeability studies.
2.4 P-gp mediates rhodamine 123 efflux by hCMEC/D3 cells 
Using non-cytotoxic concentrations of the P-gp inhibitors tariquidar or 
vinblastine, or the Breast Cancer Resistance Protein (BCRP) inhibitor fumitremorgin 
c (FTC) (data not shown), rh123 efflux from preloaded hCMEC/D3 cells was 
investigated as a means to determine P-gp functionality in this cell line. rh123 efflux 
is potentially a more sensitive measure of P-gp activity than net rh123 influx, since it 
is exclusively dependent on the efflux activity of P-gp rather than a measure of the 
relative contribution of efflux versus influx mechanisms. Compared to cells preloaded 
with rh123 and incubated at 4 oC, cellular levels of rh123 decreased sharply within 1 h 
and continued to decline thereafter. The t1/2 for rh123 efflux was estimated to be 13.3 
min [n = 3 (Fig. 5a)]. The competitive P-gp inhibitor vinblastine (22 μM) decreased 
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the rate of efflux of rh123 from hCMEC/D3 cells, [t1/2 = 112.2 min (n = 3)]. Both 
vinblastine and the allosteric P-gp inhibitor tariquidar (300 nM), but not the BCRP 
inhibitor FTC (22 μM), decreased rh123 efflux from hCMEC/D3 cells pre-loaded 
with 22 μM rh123 at 4oC for 60 min, and incubated at 37oC for 60 min (Fig. 5b). In 
addition, P-gp function in hCMEC/D3 cells was comparable to that obtained using 
primary hBECs over a 15 min efflux assay (Fig. 5c). These results demonstrate that 
rh123 efflux from hCMEC/D3 cells is largely mediated by P-gp. 
Tariquidar has been demonstrated to have a long-lasting, possible irreversible, 
inhibitory effect on P-gp (Mistry et al., 2001), whilst vinblastine acts as a competitive 
inhibitor. To investigate the mechanism of P-gp inhibition by tariquidar and 
vinblastine, hCMEC/D3 cells were pre-loaded at 4oC with 22 μM rh123 in the 
presence of either tariquidar (300 nM) or vinblastine (22 μM), followed by incubation 
at 37oC for 60 min with either vehicle or inhibitors. After preloading hCMEC/D3 cells 
with rh123 in the presence of tariquidar, rh123 efflux was inhibited in the subsequent 
incubation at 37oC, with or without the continued presence of this inhibitor (cellular 
rh123 levels were 55.7 % +/- 4.3 and 53.7 % +/- 12.2 of cells incubated at 4oC with 
and without the continued presence of tariquidar, respectively, compared to 7.02 % 
+/- 1.82 for an ethanol control. n = 3, P < 0.01). In contrast, after loading hCMEC/D3 
cells with rh123 in the presence of vinblastine, the continued presence of vinblastine 
during the incubation stage at 37oC was required to maintain efflux inhibition of 
rh123 (cellular rh123 levels compared to cells incubated at 4oC were; 50.7 % +/- 5.3 
with vinblastine present during the incubation phase, 5.8 % +/- 1.4 with vinblastine 
absent during incubation phase and 6.2 % +/- 0.56 for DMSO control). These results 
confirm previous studies that tariquidar is a long lasting P-gp inhibitor which, unlike 
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vinblastine, can exert its effect after removal from the culture medium (Mistry et al., 
2001).
2.5 P-gp restricts the apical-to-basolateral permeability of hCMEC/D3 cells to 
rh123
Since; 1) P-gp appeared polarised on the apical membrane of hCMEC/D3 
cells, and 2) rh123 was a suitable substrate to measure P-gp function using an efflux 
assay, we next investigated the permeability of hCMEC/D3 cells in a two-dimensional 
assay, to rh123, as a guide to polarised functionality (Fig. 6). The P-gp inhibitors 
vinblastine and tariquidar did not significantly affect the basolateral-to-apical 
permeability of hCMEC/D3 cells to rh123 (n = 3 P > 0.05). However, tariquidar and 
vinblastine both increased hCMEC/D3 cell apical-to-basolateral permeability to rh123 
by 67% and 55 % respectively, compared to control levels (n = 3 P < 0.05). These 
results imply that P-gp, located on the apical membrane, restricts the transport of 
rh123 in the apical-to-basolateral direction.
3. Discussion 
Human BECs express P-gp, which acts as a barrier for many therapeutic drugs 
and endogenous molecules, preventing their entry into the brain [reviewed in (Loscher 
& Potschka 2005, Schinkel 1999)]. The study of P-gp in vitro using human BECs is 
valuable for identifying potential substrates and inhibitors. The data presented here 
show, that the immortalised human BEC cell line, hCMEC/D3, expresses P-gp when 
assessed by flow cytometry, western blotting, immunocytochemistry and immuno-
electron microscopy. These data are in agreement with numerous studies that have 
demonstrated BEC P-gp expression at both the protein and mRNA level using in vitro 
- 9 -
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
cultures of both primary and immortalised cells of rat, mouse and human origin 
(Beaulieu et al., 1997; Begley et al., 1996; Miller et al., 2000; Perriere et al., 2007; 
Seetharaman et al., 1998; Tatsuta et al., 1992; Virgintino et al., 2002). In terms of P-
gp expression, the BEC phenotype appears to be preserved in hCMEC/D3 cells over a 
wide range of passages, and P-gp expression was comparable to cultured primary 
BECs, albeit slightly reduced. It is possible, however, that the cultured primary BECs 
used here have lower P-gp expression compared to isolated capillaries, which as 
demonstrated in rat and humans, more closely mimic the in vivo situation (Barrand et 
al., 1995; Regina et al., 1998; Regina et al., 1999; Seetharaman et al., 1998). Our 
observations are in agreement with those of Regina and co-workers, who reported 
lower expression of P-gp by an immortalised rat BEC cell line, RBE4, compared to 
primary rat BECs (Regina et al., 1998; Regina et al., 1999). None-the-less, the small 
difference in P-gp expression between for primary BECs and hCMEC/D3 cells did 
not result in measurable differences in P-gp function. The limited availability and 
stability of primary human cells, and the species differences between rat and human, 
makes hCMEC/D3 cells an attractive option for the study of P-gp function and 
identification of potential substrates over a large passage range. 
In this study, differential detergent fractionation of hCMEC/D3 cells showed 
that P-gp expression was localised to the membrane/organelle fraction. Using 
transmission EM and immunogold staining, P-gp was found to be localised mainly in 
or at the apical membrane, although labelling in the cytoplasm and in the basolateral 
membrane was also observed. Using EM techniques, we found ~40 % P-gp 
expression in the cytoplasm of hCMEC/D3 cells , an observation that may reflect an 
intracellular P-gp pool capable of plasma membrane translocation under certain 
conditions. Indeed, some immunolabelling appeared localized to intracellular vesicles 
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(Fig. 4a). However, it is also possible that the intracellular P-gp staining represents 
internalised P-gp targeted for degradation, or newly synthesised P-gp in transit 
towards the plasma membrane.
These results are in partial agreement with studies from rat brain tissue, 
(Bendayan et al. 2006) where abluminal, luminal and intracellular membrane 
associated (cytoplasmic vesicles, Golgi complex, and rough endoplasmic reticulum) 
staining of P-gp was detected. However, in contrast to our study, Bendayan reports 
enhanced abluminal polarisation of P-gp in rats and much greater numbers of gold 
particles per μm of membrane (1.17 ± 0.04 abluminal, 0.85 ± 0.03 luminal, compared 
to 0.038 ± 0.009 basolateral and 0.11 ± 0.17 apical, respectively, in this study). The 
greater number of gold-particles found in the study by Bendayan et al. compared to 
this study, might reflect species differences between rats and humans. The antibody 
C219 recognises P-gp epitopes that differ slightly between rats and humans, with 
potentially a higher affinity for the rodent N-terminal domain (Georges et al., 1990). 
However, in agreement with the results reported in this study, and in contrast to the 
work of Bendayan et al., numerous lines of evidence point to the polarisation of P-gp 
on the luminal membrane of BECs in rats and humans. Luminal P-gp expression has 
been observed in isolated human brain capillaries (Seetharaman et al., 1998), human 
tissue (Virgintino et al., 2002), and isolated capillaries from rats (Beaulieu et al., 
1997; Miller et al., 2000). The differing results of Bendayan et al to those of others in 
the field, including the present study, might relate to the method of fixation. 
Manoonkitiwongsa et al (Manoonkitiwongsa et al., 2000) have demonstrated that for 
Na+, K+ ATPase staining, with an increasing concentration of fixative (that has 
deleterious effects on antibody recognition), the staining decreased to a greater degree 
on the luminal than abluminal side. Therefore, it is possible that, when brain tissue 
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pieces were immersed in fixative (Bendayan et al), there would have been greater 
exposure to fixative on the luminal than abluminal sides due to the differences in 
tissue densities and hence diffusion of fluid, whereas with hCMEC/D3 cells cultured 
on inserts there would have been equal exposure. 
The results presented here also confirm functional P-gp expression by 
hCMEC/D3 cells. The t1/2 obtained here for rh123 efflux (~13 min) is in agreement 
with another study that found a t1/2 of similar magnitude in rat primary BECs (~ 10 
min) (Ji et al., 2005). However, in contrast to the relatively modest increase in the 
efflux t1/2 caused by another competitive inhibitor, verapamil, in that study (t1/2 ~ 20 
min), in the present study vinblastine caused a much more potent inhibition (t1/2 ~ 110 
min). Several factors may contribute to the differences in P-gp inhibition between this 
study and the one by Ji et al: 1) differences in P-gp expression levels between rat and 
hCMEC/D3 cells; 2) levels of ATP in the culture media; 3) differences in the method 
employed for rh123 efflux. With regards to the latter, Ji et al preloaded rat BECs at 
37oC rather than 4oC as used in this current study and the data were expressed as a 
percentage of time zero. However, rh123 cellular levels at 37oC would be influenced 
not only by passive diffusion, but also by active efflux transport making interpretation 
of results difficult. Since vinblastine and tariquidar both inhibited efflux of rh123, 
there is strong evidence that rh123 efflux from hCMEC/D3 cells is largely mediated 
by P-gp. 
In agreement with other studies, FTC, a BCRP inhibitor, did not inhibit rh123 
efflux (Weksler et al., 2005; Zhang et al., 2003). BCRP has been demonstrated to use 
rh123 as a substrate only when there is a mutation at position 482, characteristic of 
tumour cells (Alqawi et al., 2004; Sarkadi et al., 2004). Therefore, it is likely that 
hCMEC/D3 cells express wild type, non-mutated BCRP, since BCRP activity has 
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previously been demonstrated in hCMEC/D3 cells (Weksler et al. 2005). In addition, 
the inhibition of P-gp function by tariquidar was longer-lasting than that of 
vinblastine. This observation is in agreement with Mistry et al (Mistry et al., 2001), 
who reported a long-lasting inhibition of rh123 and 3H-daunorubicin efflux by 
tariquidar in a human ovarian carcinoma cell line, even if the inhibitor was only 
present in the pre-loading stage. This evidence suggests that tariquidar might be a 
more suitable inhibitor than vinblastine for the study of the role of P-gp in the 
penetration of the CNS by drugs.
Using a more relevant model of BBB transport, whereby hCMEC/D3 cells are 
grown on filters, we have demonstrated that P-gp restricts the apical-to-basolateral 
permeability of hCMEC cells to rh123. These data support our observation that P-gp 
appears localised to the apical plasma membrane in hCMEC/D3 cells as assessed by 
EM techniques and immunogold staining. In agreement, we have also recently 
reported that P-gp restricts the apical-to-basolateral, but not basolateral-to-apical, 
permeability of hCMEC/D3 cells to Aβ 1-40 (Tai et al., 2009). The restriction in 
apical-to-basolateral permeability that P-gp affords to BECs in vitro is consistent with 
the observation that, in vivo, mdr1a or mdr1a/b knock-out mice display enhanced 
CNS accumulation of many P-gp substrates, including cyclosporin A, vinblastine, 
digoxin, morphine and digoxin, colchicine and morphine [reviewed in (Loscher & 
Potschka 2005, Schinkel 1999)]. The polarised nature of P-gp function has been 
demonstrated in vitro on isolated BECs grown on filter inserts, which show 
directional transport of cyclosporin A and vincristine in mouse BECs (Shirai et al., 
1994; Tatsuta et al., 1992). 
In summary, functional P-gp expression has been demonstrated in the human 
immortalised cell line, hCMEC/D3. Importantly, hCMEC/D3 cells express P-gp 
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polarised on the apical membrane, which restricts endothelial permeability to rh123 in 
the apical-to-basolateral direction. 
4. Experimental procedures
4.1. Materials 
Tariquidar was a kind gift from Xenova (Slough, Berkshire, UK), 
Fumetrimorgan C (FTC) was from Axxora (Nottingham, Nottinghamshire, UK). 
Tissue culture plastic was from Greiner (Gloustershire, UK). All other reagents were 
from Sigma-Aldrich (Gillingham, Dorset, UK) unless stated.
4.2. Isolation of human brain endothelial cells
In procedures approved by both Kings College London and The Open 
University local ethical committee guidelines (Protocol 99-002), human brain tissue 
was obtained with written consent from patients undergoing cerebral cortical 
lobectomies, conducted at Kings College Hospital to relieve medically intractable 
seizures. The isolation of human BECs was carried out as described by Weksler et al  
(Weksler et al. 2005). Briefly, brain tissue was freed of meninges, finely chopped and 
dispersed by enzymatic digestion in Ca++ and Mg++-free Hanks buffered saline 
solution (HBSS w/o Ca++/Mg++), containing 1 mg/ml collagenase/dispase (Roche, 
Paisley, Renfrewshire UK), 20 U/ml DNase I and 0.15 μg/ml tosyl-lysyl-
chloromethylketone for 1 h at 37°C. Microvessel fragments were separated by 
density-dependent centrifugation on 25% bovine serum albumin (BSA) and subjected 
to a second digestion in collagenase/dispase solution at 37°C for 2 h. The microvessel 
fragment suspension was then centrifuged over a preformed 50 % Percoll gradient, 
washed and plated onto collagen-coated tissue culture plastic. To eliminate non-
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endothelial cells, puromycin (0.5 μg/ml) was added to the culture medium for the first 
three days following isolation. 
4.3. Cell culture
hCMEC/D3 and primary human BECs were cultured in EGM- 2 medium 
(Lonza,  Slough, Wokingham, UK) supplemented with VEGF, IGF, bFGF, 
hydrocortisone, ascorbate, gentamycin and 2.5 % fetal bovine serum (FBS) as 
indicated by the manufacturer. Cells were grown on collagen-coated (5 mg/ml, 1h 
RT) tissue culture plastic in a humidified atmosphere at 37oC in 5 % CO2. For all 
experiments, BECs were grown to confluence and left for 2 days prior to treatment (~ 
1 x 105 cells / cm2), with the EGM-2 medium changed every 2-3 days. 
4.4. Western blotting 
Confluent hCMEC/D3 cells were lysed in 500 μl of RIPA buffer containing 1 
mM phenylmethylsulphonyl fluoride (PMSF) and 10 ng/ml of aprotinin, leupeptin 
and pepstatin A. Protein levels were measured by the Biorad DC protein assay (Hemel 
Hempstead, Hertfordshire, UK). Samples were denatured in 1 x Laemmli’s buffer and 
20 μg of protein were loaded on SDS-PAGE gels appropriate for the molecular 
weight of each protein under investigation. Proteins were resolved and transferred to a 
nitrocellulose membrane. After incubation with primaries antibodies overnight at 4oC 
(Table 1), membranes were incubated with a species-specific secondary antibody 
conjugated to horseradish peroxidase for 1 h at room temperature [1 in 10,000 dilution 
(Pierce Biotechnology, Tattenhoe, Cheshire, UK)], and were visualised by enhanced 
chemiluminescence detection (ECL, Amersham, Buckinghamshire, UK). For some 
blots, to confirm equal loading, membranes were stripped in buffer [2 % (w/v) SDS, 
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0.0625 M Tris pH 6.8, 0.008 % (v/v) β-mecaptoethanol] and re-probed with mouse 
monoclonal anti-actin (1 μg/ml). The signal intensities of the bands were then 
normalised to actin. 
4.5. Differential detergent fractionation
hCMEC/D3 whole cell lysates were separated into cytosolic, 
membrane/organelle, nuclear and cytoskeletal fractions using differential detergent 
fractionation as described by Ramsby et al (Ramsby et al., 1994). Briefly, hCMEC/D3 
cells were grown to confluence in 75 cm2 flasks, washed in HBSS w/o Ca++/Mg++ and 
detached with 0.25 % v/v porcine trypsin and 0.02 % w/v EDTA. After centrifugation 
(500 x g, 10 min, 4oC), cells were lysed at 4oC in 250 μl of 10 mM piperazine- 1, 4’-
bis (2-ethanesulphonic acid) (PIPES) buffer pH 6.8, containing 300 nM sucrose, 100 
mM NaCl, 3 mM MgCl2, 5 mM EDTA, 1.2 mM PMSF and 0.01 % w/v digitonin. 
After centrifugation (500 x g, 10 min, 4oC), supernatants (cytosolic protein fraction) 
were collected  and the pellets were re-suspended on ice for 20 min in 250 μl of 10 
mM PIPES pH 7.4 buffer containing 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2 , 
3 mM EDTA, 1.2 mM PMSF and 0.5 % v/v triton X-100. After centrifugation (5000 
x g, 10 min, 4oC), supernatants (containing membrane/organelle fraction) were 
collected and the remaining pellets were re-suspended on ice for 10 min in 125 μl of a 
10 mM PIPES pH 7.4 buffer containing 10 mM NaCl, 1 mM MgCl2, 1.2 mM PMSF, 
0.5 % v/v triton X-100, 1 % v/v tween-40 and 0.5 % wt/vol sodium deoxycholate. 
After centrifugation (7000 x g, 10 min, 4oC), supernatants (containing nuclear 
proteins) were collected, whilst the pellet contained the cytoskeletal proteins. All 
fractions were dissolved in 1 x Laemmli’s buffer. Aliquots for each subcellular 
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fraction equivalent to the same cell sample were loaded on SDS-PAGE gels and 
subjected to electrophoresis and immunoblotting as described above.
4.6. Flow cytometry
Fully confluent hCMEC/D3 and primary BECs were detached as described 
above and fixed in 4 % w/v p-formaldehyde (PAF) for 10 min. After one wash in 
phosphate buffer saline (PBS), cells were blocked and permeabilised for 30 min [0.1 
% w/v triton X-100, 3 % w/v normal goat serum (NGS) in PBS], then incubated 
overnight at 4oC with an anti-P-gp antibody (see Table 1) or an isotype-matched 
antibody as a negative control. hCMEC/D3 cells were then washed three times in PBS 
and incubated with 10 μg/ml of a fluorescein inisothiocyanate (FITC) - conjugated 
goat anti-mouse IgG antibody (Chemicon, Chandlers Ford, Hampshire, UK). After 
two final washes with PBS, the cells were suspended in 500 μl PBS and analysed 
using a FACSCalibur flow cytometer with Cellquest software [488 nm λexcitation, 530 
nm λemission, (Becton Dickinson, Oxford, Oxfordshire, UK)]. For each sample the 
median fluorescence of 10,000 cells was determined. 
4.7. Immunocytochemistry 
hCMEC/D3 cells were grown to fully confluence on collagen coated glass 
coverslips (5 mg/ml, 1 h). Cells were then fixed in methanol at -20oC for 10 min, and 
washed 3 times in PBS. An anti-P-gp antibody (Table 1) or isotype matched control 
antibody was then added to the fixed cells overnight at 4oC. After three 10 min 
washes in PBS, a 1 in 100 dilution of Alexa Fluor-555 (Molecular probes, Eugene, 
Oregon, US) conjugated goat anti-mouse antibody was added for 1 h at RT. After 2 
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final washes in PBS, the slides were mounted and viewed with a fluorescence 
microscope (Olympus,Watford, Hertfordshire,UK).
4.8. Transmission electron microscopy combined with immunogold labelling
For the detection of P-gp at the ultrastructural level, the method of Bendayan 
et al (Bendayan et al., 2006) was followed with modifications. Briefly, hCMEC/D3 
cells were grown to confluence on collagen- and fibronectin- coated transwell 
polyester membrane inserts and left for 2 days. hCMEC/D3 cells were then fixed for 
21 h (6 h RT, 15 h 4oC) in phosphate buffer (PB) containing 2 % w/v PAF, 0.01 M 
sodium m-periodate and 0.075 M lysine. Post fixation, hCMEC/D3 cells were washed 
twice with PB (1–5 min), cut into 2 mm strips and processed using ‘progressive 
lowering of temperature’ with a Leica AFS2 automatic freeze substitution system 
(Leica, Milton Keynes, Buckingham UK). This method involves the progressive 
lowering of temperature from 0o to -30oC whilst increasing the methanol content of 
the solution. hCMEC/D3 cells were infiltrated in the acrylic resin Lowicryl K4M 
(Agar Scientific, Essex, UK) and polymerised at -30oC under ultra violet (UV) light. 
Ultrathin 80 nm sections of the membrane insert were then cut using a Diatome 
diamond knife on a Leica ultra-microtome (Leica UCT, Leica, Buckinghamshire UK). 
The sections were mounted on formvar (Agar Scientific, Stanstead, Essex, UK) 
coated nickel slot grids. Non-specific binding was blocked using 1 % (w/v) 
ovalbumin in 0.01 M PBS for 30 min at RT. Grids were incubated with droplets of an 
anti-P-gp antibody (Table 1) or an isotype-matched control overnight at RT, washed 
(three times for 5 min in PBS), blocked (1 % w/v ovalbumin, 10 min , RT) and 
incubated with a goat anti-mouse IgG secondary antibody conjugated to 10 nm gold 
particles for 2 h at RT (British Biocell International, Cardiff, Cardiff, Wales). The 
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samples were then washed (three times for 5 min in PBS), fixed in 2.5 % w/v 
glutaraldehyde in PBS (Agar Scientific, Stanstead, Essex, UK), washed (twice for 5 
min in PBS then 1 min with deionised water), allowed to air dry and counterstained 
with 4 % w/v aqueous uranyl acetate (Agar Scientific, Essex, UK)  for 15 min. After a 
final three washes in distilled water the sections were examined using a JEOL JEM 
1400 transmission electron microscope operating at 80 kV. The images were acquired 
using an AMT XR60 11 mega pixel digital camera calibrated for magnification such 
that each image displayed a scale marker. Images of 7.5 μm lengths of membrane 
were taken every 2-3 frames for a total of 500 μm membrane. For both the apical and 
basolateral membranes, the number of gold particles within 100 nm of the membrane 
were counted in each 7.5 μm length of membrane and expressed as gold particles per 
1 μm of plasma membrane. The number of cytoplasmic gold particles not within 100 
nm of the plasma membrane were also counted, and expressed as a percentage of total 
gold particles.   
4.9. Rhodamine 123 efflux assay
hCMEC/D3 cells were grown to confluence and detached.1 x 106 cells/ml 
hCMEC/D3 cells were preloaded by incubation with efflux buffer [RPMI-1640,
(Lonza,  Slough, Wokingham, UK) containing 1 % w/v BSA] containing 10 μg/ml 
(22 μM) rh123 on ice for 1 h. Rh123-preloaded cells were washed twice in efflux 
buffer and redistributed into different tubes for each test condition (2.5 x 105 cells 
were used for each sample). Duplicate tubes were placed at 4oC in efflux buffer, 
whilst the remaining tubes were incubated at 37oC in the presence of vinblastine (22 
μM dissolved in DMSO) or DMSO only in efflux buffer. At 15, 30, 60, 120, 180 and 
360 min intervals, tubes containing 2.5 x 105 cells were removed and placed on ice for 
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the remainder of the experiment. After all samples had been collected, cells were 
washed twice in PBS and resuspended in 500 µl PBS. Cell samples were then read 
using a FACSCalibur with Cellquest software (Becton Dickson) and the median 
fluorescence of 10,000 cells per sample recorded. The median fluorescence intensity 
of a negative control (cells not loaded with rh123) was subtracted from all the other 
treatments and the data expressed as a percentage of rh123 preloaded cells kept at 
4oC. For some experiments, the effect of vinblastine [competitive P-gp and MRP-1 
inhibitor (22 μM)], tariquidar [specific P-gp inhibitor (300 nM dissolved in ethanol)] 
or FTC (competitive BCRP inhibitor (22 μM, dissolved in DMSO)] on rh123 
accumulation in hCMEC/D3 cells or primary hBECs incubated at 37oC for the 
indicated periods of time was tested. In these experiments, cells were preloaded with 
either rh123 alone or in the presence of an inhibitor.
4.10. Rh123 permeability assay
hCMEC/D3 cells were grown to confluence on transwell polyester membrane 
inserts [Corning Costar, High, Wycombe, Buckinghamshire, UK (0.4 µm pore, 12mm 
diameter)], which were first coated with collagen as before and then with fibronectin 
(5 μg/ml for 1 h). The paracellular permeability to rh123 of the hCMEC/D3 
monolayers was then investigated. Briefly, 2µM rh123 and 0.1 mM 14C Inulin [1-3 
µCi/mg (MP biomedicals, Solon, Ohio, USA)] alone or in the presence of tariquidar 
(300 nM), or vinblastine (22 µM) was added to the apical chamber, and the 
fluorescence and β-emission counter that crossed to the basolateral chamber was 
determined over 30 min, in successive 5 min periods, using a BMG plate reader 
(Offenberg, Germany) and β-counter (Wallac trilux, Perkin Elmer, Cambridge, 
Cambridgeshire, UK). The volume cleared was plotted against time, and the slopes of 
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the curves used to calculate the permeability coefficients (Pe, cm/min) of the 
endothelial cell monolayer: 
Pe = PS/s, where PS (clearance) is the permeability surface area of the 
endothelial monolayer and s is the surface area of the filter (1.1 cm2). 
PS is given by: 1/PS = 1/me – 1/mf, where and, me and mf are the slopes of the 
curves corresponding to endothelial cells on filters and to filters only, respectively. me 
and mf were calculated by plotting the cleared volume against time. 
The cleared volume was calculated by: (AUa- AUb)/Fi, where AUa is the total 
fluorescence (arbitrary units) in the basal compartment, AUb is the background 
fluorescence and Fi is the fluorescence of the initial solution (AU/ml). 
To investigate the basolateral-to-apical permeabilty, 1.5 ml rh123 (22 μM) and 
0.1 mM 14C Inulin was added to the basolateral chamber of a 12 well plate [+/- 
tariquidar (300 nM), vinblastine (22 μM) or FTC (22  μM)] and filters containing the 
appropriate inhibitors placed into the well. The filter was left in place for 30 min and 
the fluorescence and β-emission of the apical and basolateral chambers measured. The 
Pe values were calculated using the assumption that the curve was linear:
PSef = [(AUa- AUb)/Fi] / 30
In order to eliminate the influence of paracellular leakage of in the rh123 
permeability experiments, a clearance quotient was calculated using the following 
formula;
4.11. Statistical analysis
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All data are represented as means +/- SEM and the number of experiments, n, 
is indicated each time. Statistical significance was determined using ANOVA 
followed by Student’s t test, comparing each treatment to the appropriate control (* P 
< 0.05).  For rh1213 permeability, a paired t test was used, since the data was paired.
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Fig. 1. The expression of P-gp by hCMEC/D3 and primary hBECs . (a) Fully 
confluent hCMEC/D3 cells (passage 23-28) and primary hBECs (passage 2-4) were 
fixed in 4% PAF, permeabilised using 0.1% triton X-100 and stained with antibodies 
for P-gp (JSB-1, mouse monoclonal IgG1) or an isotype matched negative control 
(mouse IgG1), and analysed via flow cytometry. Data represents mean ± SEM, n = 3 
with duplicate samples. ** P < 0.01 using Student’s t test (b) Immunoblots of 
hCMEC/D3 cell whole cell lysates stained with antibodies for P-gp and actin between 
passage 23 and 44. (c) The signal intensity of the bands corresponding to P-gp and 
actin were determined using Image J software and P-gp expression was normalised 
against actin. Results from one experiment. 
Fig. 2.  Expression of P-gp by hCMEC/D3 cells as viewed by fluorescence 
microscopy. hCMEC/D3 cells (p 28) were grown to confluence on collagen coated 
glass coverslips. Cells were fixed, permeabilised and stained for P-gp using either the 
antibody C219 (b), or JSB-1 (d) or isotype matched controls (a,c), as described in the 
Methods. Images are from one experiment representative of three. Scale bar 
represents 50 µm.
Fig. 3. Sub-cellular distribution of P-gp by hCMEC/D3 cells as assessed by 
differential detergent fractionation. (a) Fully confluent hCMEC/D3 cells were 
separated into 1) cytosol, 2) membrane/organelle, 3) nuclear and 4) cytoskeletal 
components using differential detergent fractionation and the expression of Sp3, actin 
and P-gp was assessed by western blotting. (b) Relative expression of each protein in 
cytosol, membrane/organelle, nuclear and cytoskeletal fractions as a percentage of 
total expression. Data represents mean ± SEM, n = 3.
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Fig. 4. The expression of P-gp as detected via transmission electron microscopy 
and immunogold labelling. hCMEC/D3 cells (p 28) were grown to confluence on 
transwell polyester membrane inserts and stained for P-gp as described in the 
Methods. a, b, and c are representative images of gold particles found intracellularly 
and on the basolateral and apical membranes, respectively. (d) One frame length of 
7.5 μm was taken every 2-3 frames for a total of 500 μm, and the number of gold gold 
particles counted within 100 nm (shown as scale bar) of the apical or basolateral 
membrane was quantified. * P < 0.05, ** P < 0.01, ** P < 0.001 using Student’s t 
test. Arrows indicate immunolabelling with gold particles.
Fig. 5. Time-dependent efflux of rh123 by hCMEC/D3 cells. (a) Fully confluent 
hCMEC/D3 cells were preloaded with rh123 (22 μM) for 1 h at 4oC and then 
incubated at 37oC in the presence of 22 µM vinblastine or DMSO (control) for 15, 30, 
60, 120, 180 or 360 min. The cells were analysed by flow cytometry (488 nm λexcitation 
520 nm λemission). The median fluorescence intensity was measured and expressed as a 
percentage of preloaded cells incubated at 4oC. (b and c) hCMEC/D3 or (c) primary 
human BECs  were preloaded with rh123 (22 μM) at 4oC for 60 min followed by (b) 
60 min or (c) 15 min incubation at 37 oC in the presence of tariquidar (300 nM), 
vinblastine (22 μM), FTC (22 μM) or an appropriate control and the median 
fluorescence intensity measured by flow cytometry. Data represents mean ± SEM, n = 
3 with duplicate samples for hCMEC/D3 cells (a, b and c) and n=3 from two different 
donors for primary hBEC (c). * P < 0.05, ** P < 0.01 using Student’s t test.
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Fig. 6. The permeability of hCMEC/D3 cells to rh123 in the presence or absence 
of tariquidar and vinblastine.  hCMEC/D3 cell were grown to confluence on 
collagen- and fibronectin- coated filter inserts. rh123 (22 μM) and 0.1 mM 14C Inulin 
was then added to the apical or basolateral side of the filter in the presence of 
tariquidar (300 nM), vinblastine (22 µM) or DMSO control. The rh123 clearance 
quotient was then calculated as described in the methods section. Data represents 
mean ± SEM, n = 4 (a), or 3 (b) with duplicate samples. * P < 0.05 using a paired t-
test.
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Anti- Species WB ICC FC TEM Source
P-gp 
(C219)
Mouse 
monoclonal IgG2a
500 ng/
ml
5 μg/ml - 5 μg/ml Abcam, 
Cambridgeshire, 
UK
P-gp 
(JSB1)
Mouse 
monoclonal IgG1
 - 5 μg/ml 5 μg/ml - Abcam, 
Cambridgeshire, 
UK
SP3 Mouse 
monoclonal IgG2a
200 ng/
ml
- - - Santa Cruz, 
California, USA
β-actin Mouse 
monoclonal IgG1
1 μg/ml - - - Sigma-Aldrich, 
Dorset, UK
- Mouse 
monoclonal IgG1
- 5 μg/ml 5 μg/ml - Sigma-Aldrich, 
Dorset, UK
- Mouse 
monoclonal IgG2a
- 5 μg/ml - 5 μg/ml Sigma-Aldrich, 
Dorset, UK
Table 1. Antibodies and concentrations used in this study. WB, western blotting; 
ICC, immunocytochemistry; FC, flow cytometry; TEM, transmission electron 
microscopy. 
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